Legislation governing the US incentive scheme for neglected diseases needs to be amended, urges MSFBMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g5861 (Published 30 September 2014) Cite this as: BMJ 2014;349:g5861
- Jennifer Reid, researcher1,
- Julien Potet, policy adviser (neglected tropical diseases, vaccines)2,
- Katy Athersuch, medical innovation and access policy adviser3,
- Maisy Grovestock, policy intern3,
- Judit Rius Sanjuan, US manager and legal policy adviser1
- 1Médecins Sans Frontières—Access Campaign, 333 7th Avenue, 2nd Floor, New York, NY 10001, USA
- 2Médecins Sans Frontières—Access Campaign, 8 Rue Saint Sabin, 75011 Paris, France
- 3Médecins Sans Frontières—Access Campaign, Rue de Lausanne 78, CH-1211 Geneva 21, Switzerland
As a medical humanitarian organisation diagnosing and treating people with neglected diseases for almost 30 years,1 2 Médecins Sans Frontières (MSF) understands only too well that the dearth of research and development for new tools to treat these diseases3 is directly attributable to insufficient funding and incentives.
Innovative incentive mechanisms for research and development, including “pull” mechanisms, such as the US Food and Drug Administration priority …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial